Promoter holding
64.27%
BP
Bharat Parenterals Limited - Due diligence report
A 360° intelligence report on Bharat Parenterals: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Bharat Parenterals — 360° Intelligence Report
Generated from MCA filings & public records79/100
Trust Score
Low Risk
Bharat Parenterals is assessed as Low Risk with a Trust Score of 79/100. Bharat Parenterals is an active public limited indian non-government company incorporated in 1992, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 15 Aug 2026 from the latest processed filings. Bharat Parenterals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
79/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 15 open (145.35 cr) · 26 satisfied (34.12 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 27 | 48.0 cr |
| Others | 3 | 48.0 cr |
| Sidbi | 1 | 48.0 cr |
| Hdfc Bank Limited | 8 | 48.0 cr |
| Bank Of Baroda | 1 | 48.0 cr |
| Axis Bank Ltd | 1 | 48.0 cr |
Compliance Score: 42/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: BSE.
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (1176 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MUKESHBHAI JIVRAJBHAI PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY PARASMAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JIGNESH NITINCHANDRA SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHARATKUMAR RAMESHCHANDRA DESAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHAILESHKUMAR GHABHAWALA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KRUTIKA PADMAKAR BHATTBHATT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ZANKHANA BIMALKUMAR SHETH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HEMANG JAYENDRABHAI SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Sharmin Nareshkumar Soni | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Alkesh Jayantilal Shah | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 10 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
2
Group entities
3
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Varenyam Biolifesciences Private Limited | Subsidiary Company | 74.00% |
| Innoxel Lifesciences Private Limited | Subsidiary Company | 74.00% |
| Desai Shares And Stock Private Limited | Associate Company | 74.00% |
Key managerial personnel: JIGNESH NITINCHANDRA SHAH (CFO) · BHARATKUMAR RAMESHCHANDRA DESAI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 33+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (42/100).
15 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 16.05 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence68/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment75/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 15 open charge(s) of 145.35 cr already registered.
- Compliance gaps should be priced into terms.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events15 Jul 2026
Charge created
Hdfc Bank Limited - 25.50 Lakh
16 Feb 2026
Charge created
Others - 1.39 cr
17 Dec 2025
Charge created
Sidbi - 12.00 cr
26 Nov 2025
Charge created
Hdfc Bank Limited - 12.86 Lakh
26 Sep 2025
Last AGM held
Annual general meeting
28 Jul 2025
Director appointed
Alkesh Jayantilal Shah (Director)
02 Jul 2025
Charge satisfied
Others
07 May 2025
Director appointed
Sharmin Nareshkumar Soni (Company Secretary)
31 Mar 2025
Latest balance sheet
Filed with ROC
16 Dec 2024
Charge created
Hdfc Bank Limited - 21.50 Lakh
12 Dec 2024
Charge satisfied
Hdfc Bank Limited
06 Nov 2024
Charge satisfied
Hdfc Bank Limited
18 Oct 2024
Charge satisfied
Others
21 Sep 2024
Charge created
Hdfc Bank Limited - 78.00 Lakh
31 Jul 2024
Charge created
Hdfc Bank Limited - 70.30 Lakh
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
10 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 2 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Tfl | L24119TN1971PLC006083 | Chennai, Tamil Nadu, India |
| Metropolitan Eximchem | U19202MH1968PTC014067 | Sion, Maharashtra, India |
| Shivalik Crop Sciences Private Limited | U24302CH2016PTC041040 | Chandigarh, Chandigarh, India |
| Aristo Biotech | L01100GJ2005PLC127397 | Vadodara, Gujarat, India |
| Mangalam Drugs & Organics | L24230MH1972PLC116413 | Mumbai, Maharashtra, India |
| Foglagroup | U24111WB2004PTC099677 | Kolkata, West Bengal, India |
| Astron Zircon Private Limited | U26933GJ2011PTC067384 | Ahemedabad, Gujarat, India |
| Fortis Chemicals Private Limited | U24110OR2005PTC025923 | Kolabira, Orissa, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Bharat Parenterals before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Bharat Parenterals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Bharat Parenterals - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 79/100, distress signals and MSME payment-delay disclosures - know whether Bharat Parenterals pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Bharat Parenterals - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Bharat Parenterals an active company?
Bharat Parenterals has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).
Is Bharat Parenterals financially healthy?
Bharat Parenterals has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Bharat Parenterals?
Its overall Trust Score is 79/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Bharat Parenterals?
Promoters hold a minority stake - exact percentages are in the full report. 10 active director(s) are on record.
Does Bharat Parenterals have loans or charges against its assets?
15 open charge(s) are registered against its assets, and 26 earlier charge(s) stand satisfied.
Is Bharat Parenterals up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).
Is it risky to lend to Bharat Parenterals?
Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
